Shares of China's CanSino Biologics rise as much as 15% on W...
Shares of China's CanSino Biologics rise as much as 15% on Wednesday afternoon.
Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable.
康希诺生物日内走高，一度涨超15%，此前宣布与Aerogen合作开发全球首款吸入式新冠疫苗。Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable.
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
